Remove 2026 Remove Biosimilars Remove Drug Development
article thumbnail

Sandoz to build Slovenian biosimilar development facility

European Pharmaceutical Review

To support future growth of its biosimilar pipeline, Sandoz is planning to build a Biosimilar Technical Development Center in Slovenia. The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026.

article thumbnail

Sandoz partners with Just–Evotec Biologics to develop and manufacture multiple biosimilars

Express Pharma

The agreement covers the development and manufacture of multiple biosimilar medicines with an option for expansion. Development of the biosimilars will ramp-up over the coming 12-18 months.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

August 2023 Newsletter

Safe Biologics

A Better Reform: Ensuring Savings Are Passed Onto Patients While price-setting proponents say beneficiaries will start to see lower drug prices beginning in 2026, there’s no evidence that this is true, and there are better ways to lower out-of-pocket costs- and much faster, Reilly explains. – View clip.

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare.

article thumbnail

A Temporary Extension for the Rare Pediatric Disease Priority Review Voucher with a Longer-Term Extension in Sight?

FDA Law Blog: Biosimilars

No rare pediatric disease vouchers could be awarded even to designated applications after September 30, 2026. It is extremely difficult, if not impossible, to do the long-term planning and substantial fundraising required for drug development without knowing whether such an important and valuable incentive will be there.

article thumbnail

Medicare Price “Negotiations” Will Jeopardize Patient Access to New Medicines, Result in Worse Health Outcomes

Safe Biologics

A Better Reform: Ensuring Savings Are Passed Onto Patients While price-setting proponents say beneficiaries will start to see lower drug prices beginning in 2026, there’s no evidence that this is true, and there are better ways to lower out-of-pocket costs- and much faster, Reilly explains.